

**SINGAPORE  
BIOTECH INVEST**

**21-22 March 2017**

Singapore Exchange (SGX)

**HONG KONG  
BIOTECH INVEST**

**23-24 March 2017**

KPMG Hong Kong

**AUSTRALIA-CHINA  
BIOTECH INVEST**

**27-28 March 2017**

Shanghai Marriott Hotel City Centre

**Paul Rennie, Managing Director, Paradigm BioPharma**

Paul Rennie, Managing Director Paul Rennie BSc, MBM, Grad Dip Commercial Law, MSTC, has extensive sales, marketing, business development, operational and IP commercialisation experience in the biopharmaceutical sector. Paul's experience includes working for Boehringer Mannheim (now Roche Diagnostics), Merck KGGA as national sales and marketing manager and Soltec (FH Faulding Ltd) as their director of business development. Paul also led the commercialisation of Recaldent® a novel biopharmaceutical arising from research at the dental school, University of Melbourne. Paul took this R&D project from the laboratory bench to a commercial product now marketed globally as an additive to oral care products. More recently Paul worked in a number of positions with Mesoblast Ltd. Paul was the inaugural COO and moved into Executive Vice President New Product Development for the adult stem cell company. Paul founded Paradigm in early 2015.